{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T19:07:12Z","timestamp":1789067232697,"version":"build-2803163510"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with a 5-year survival rate of approximately 5\u20137%, and complete surgical resection remains the only curative treatment but is often unfeasible. Fluorescence-guided surgery (FGS) using tumor-targeted probes may improve tumor visualization and facilitate complete resection. This study aimed to identify and validate tumor targets for FGS during PDAC resection procedures. RNA expression data from over 4000 cell surface genes, obtained from public genomic databases, were analyzed to identify genes encoding PDAC-associated proteins. Eleven potential tumor targets were identified, including CEACAM5, TMPRSS4, COL17A1, CLDN18, and AQP5. Protein expression was evaluated by immunohistochemistry (IHC) in tissues from 44 PDAC and 7 chronic pancreatitis (CP) patients. All targets, except COL17A1, showed significantly higher expression in PDAC tissue compared to healthy pancreatic, CP, and duodenal tissue (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001), as well as in tumor-positive versus tumor-negative lymph nodes. Especially CEACAM5, TMPRSS4, and AQP5 were identified as the most promising targets for distinguishing PDAC from healthy tissues and detecting lymph node metastasis during FGS. The development of probes targeting multiple markers, such as AQP5 with CEACAM5 and\/or TMPRSS4, may help overcome interpatient variability and enhance detection across patients.\n                  <\/jats:p>","DOI":"10.1038\/s41598-025-00517-1","type":"journal-article","created":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T13:24:59Z","timestamp":1747401899000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Evaluation of tumor targets selected from public genomic databases for imaging of pancreatic ductal adenocarcinoma"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-7540-1476","authenticated-orcid":false,"given":"Nada","family":"Badr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca Ten","family":"Elshof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben D.","family":"Houvast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lysanne D. A. N.","family":"de Muynck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Stijn L. P.","family":"Crobach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard J. P.","family":"van Westen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald L. P.","family":"van Vlierberghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Sven D.","family":"Mieog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander L.","family":"Vahrmeijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J. K.","family":"Kuppen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,16]]},"reference":[{"key":"517_CR1","doi-asserted-by":"publisher","unstructured":"Adamska, A., Domenichini, A. & Falasca, M. Pancreatic ductal adenocarcinoma: current and evolving therapies. Int. J. Mol. Sci. 18 https:\/\/doi.org\/10.3390\/ijms18071338 (2017).","DOI":"10.3390\/ijms18071338"},{"key":"517_CR2","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1002\/bjs.11115","volume":"106","author":"WS Tummers","year":"2019","unstructured":"Tummers, W. S. et al. Impact of resection margin status on recurrence and survival in pancreatic cancer surgery. Br. J. Surg. 106, 1055\u20131065. https:\/\/doi.org\/10.1002\/bjs.11115 (2019).","journal-title":"Br. J. Surg."},{"key":"517_CR3","doi-asserted-by":"publisher","first-page":"56816","DOI":"10.18632\/oncotarget.18232","volume":"8","author":"WS Tummers","year":"2017","unstructured":"Tummers, W. S. et al. Selection of optimal molecular targets for tumor-specific imaging in pancreatic ductal adenocarcinoma. Oncotarget 8, 56816\u201356828. https:\/\/doi.org\/10.18632\/oncotarget.18232 (2017).","journal-title":"Oncotarget"},{"key":"517_CR4","doi-asserted-by":"publisher","first-page":"16211","DOI":"10.1038\/s41598-020-73242-6","volume":"10","author":"FA Vuijk","year":"2020","unstructured":"Vuijk, F. A. et al. Molecular targets for diagnostic and intraoperative imaging of pancreatic ductal adenocarcinoma after neoadjuvant FOLFIRINOX treatment. Sci. Rep. 10, 16211. https:\/\/doi.org\/10.1038\/s41598-020-73242-6 (2020).","journal-title":"Sci. Rep."},{"key":"517_CR5","doi-asserted-by":"publisher","first-page":"3999","DOI":"10.1245\/s10434-014-3810-7","volume":"21","author":"A Gerritsen","year":"2014","unstructured":"Gerritsen, A. et al. Preoperative characteristics of patients with presumed pancreatic cancer but ultimately benign disease: a multicenter series of 344 pancreatoduodenectomies. Ann. Surg. Oncol. 21, 3999\u20134006. https:\/\/doi.org\/10.1245\/s10434-014-3810-7 (2014).","journal-title":"Ann. Surg. Oncol."},{"key":"517_CR6","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1007\/s00534-012-0534-6","volume":"19","author":"FP Verbeek","year":"2012","unstructured":"Verbeek, F. P. et al. Image-guided hepatopancreatobiliary surgery using near-infrared fluorescent light. J. Hepatobiliary Pancreat. Sci. 19, 626\u2013637. https:\/\/doi.org\/10.1007\/s00534-012-0534-6 (2012).","journal-title":"J. Hepatobiliary Pancreat. Sci."},{"key":"517_CR7","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1097\/MPA.0000000000001075","volume":"47","author":"WS Tummers","year":"2018","unstructured":"Tummers, W. S. et al. Advances in diagnostic and intraoperative molecular imaging of pancreatic Cancer. Pancreas 47, 675\u2013689. https:\/\/doi.org\/10.1097\/MPA.0000000000001075 (2018).","journal-title":"Pancreas"},{"key":"517_CR8","doi-asserted-by":"publisher","unstructured":"de Muynck, L. et al. Consensus Statement on the Use of Near-Infrared Fluorescence Imaging during Pancreatic Cancer Surgery Based on a Delphi Study: Surgeons\u2019 Perspectives on Current Use and Future Recommendations. Cancers (Basel). 15. https:\/\/doi.org\/10.3390\/cancers15030652 (2023).","DOI":"10.3390\/cancers15030652"},{"key":"517_CR9","doi-asserted-by":"publisher","first-page":"3990","DOI":"10.1158\/1078-0432.CCR-19-4156","volume":"26","author":"KS de Valk","year":"2020","unstructured":"de Valk, K. S. et al. First-in-Human assessment of cRGD-ZW800-1, a zwitterionic, Integrin-Targeted, Near-Infrared fluorescent peptide in Colon carcinoma. Clin. Cancer Res. 26, 3990\u20133998. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-4156 (2020).","journal-title":"Clin. Cancer Res."},{"key":"517_CR10","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1593\/tlo.10220","volume":"4","author":"M van Oosten","year":"2011","unstructured":"van Oosten, M., Crane, L. M., Bart, J., van Leeuwen, F. W. & van Dam, G. M. Selecting potential targetable biomarkers for imaging purposes in colorectal Cancer using target selection criteria (TASC): A novel target identification tool. Transl Oncol. 4, 71\u201382. https:\/\/doi.org\/10.1593\/tlo.10220 (2011).","journal-title":"Transl Oncol."},{"key":"517_CR11","doi-asserted-by":"publisher","first-page":"3350","DOI":"10.1245\/s10434-018-6655-7","volume":"25","author":"CES Hoogstins","year":"2018","unstructured":"Hoogstins, C. E. S. et al. Image-Guided surgery in patients with pancreatic cancer: first results of a clinical trial using SGM-101, a novel carcinoembryonic Antigen-Targeting, Near-Infrared fluorescent agent. Ann. Surg. Oncol. 25, 3350\u20133357. https:\/\/doi.org\/10.1245\/s10434-018-6655-7 (2018).","journal-title":"Ann. Surg. Oncol."},{"key":"517_CR12","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/S2468-1253(20)30088-1","volume":"5","author":"G Lu","year":"2020","unstructured":"Lu, G. et al. Tumour-specific fluorescence-guided surgery for pancreatic cancer using panitumumab-IRDye800CW: a phase 1 single-centre, open-label, single-arm, dose-escalation study. Lancet Gastroenterol. Hepatol. 5, 753\u2013764. https:\/\/doi.org\/10.1016\/S2468-1253(20)30088-1 (2020).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"517_CR13","doi-asserted-by":"publisher","first-page":"82","DOI":"10.2967\/jnumed.121.263773","volume":"64","author":"BGS Mulder","year":"2023","unstructured":"Mulder, B. G. S. et al. Intraoperative molecular fluorescence imaging of pancreatic Cancer by targeting vascular endothelial growth factor: A multicenter feasibility Dose-Escalation study. J. Nucl. Med. 64, 82\u201389. https:\/\/doi.org\/10.2967\/jnumed.121.263773 (2023).","journal-title":"J. Nucl. Med."},{"key":"517_CR14","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s40291-022-00635-w","volume":"27","author":"RD Houvast","year":"2023","unstructured":"Houvast, R. D. et al. Prediction of biomarker expression on primary pancreatic ductal adenocarcinoma tissues using Fine-Needle biopsies: paving the way for a Patient-Tailored molecular imaging approach. Mol. Diagn. Ther. 27, 261\u2013273. https:\/\/doi.org\/10.1007\/s40291-022-00635-w (2023).","journal-title":"Mol. Diagn. Ther."},{"key":"517_CR15","doi-asserted-by":"publisher","unstructured":"Houvast, R. D. et al. An immunohistochemical evaluation of Tumor-Associated glycans and mucins as targets for molecular imaging of pancreatic ductal adenocarcinoma. Cancers (Basel). 13. https:\/\/doi.org\/10.3390\/cancers13225777 (2021).","DOI":"10.3390\/cancers13225777"},{"key":"517_CR16","doi-asserted-by":"publisher","unstructured":"van Dam, M. A. et al. Overview and future perspectives on Tumor-Targeted positron emission tomography and fluorescence imaging of pancreatic Cancer in the era of neoadjuvant therapy. Cancers (Basel). 13. https:\/\/doi.org\/10.3390\/cancers13236088 (2021).","DOI":"10.3390\/cancers13236088"},{"key":"517_CR17","doi-asserted-by":"publisher","first-page":"e1000046","DOI":"10.1371\/journal.pmed.1000046","volume":"6","author":"HC Harsha","year":"2009","unstructured":"Harsha, H. C. et al. A compendium of potential biomarkers of pancreatic cancer. PLoS Med. 6, e1000046. https:\/\/doi.org\/10.1371\/journal.pmed.1000046 (2009).","journal-title":"PLoS Med."},{"key":"517_CR18","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.ejogrb.2023.07.007","volume":"288","author":"F Tummers","year":"2023","unstructured":"Tummers, F. et al. Biomarker identification for endometriosis as a target for real-time intraoperative fluorescent imaging: A new approach using transcriptomic analysis to broaden the search for potential biomarkers. Eur. J. Obstet. Gynecol. Reprod. Biol. 288, 114\u2013123. https:\/\/doi.org\/10.1016\/j.ejogrb.2023.07.007 (2023).","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"517_CR19","unstructured":"Euretos - Data drive disease insight, https:\/\/www.euretos.com (."},{"key":"517_CR20","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1007\/s11307-022-01791-5","volume":"25","author":"RPJ Meijer","year":"2023","unstructured":"Meijer, R. P. J. et al. Data-Driven identification of targets for Fluorescence-Guided surgery in Non-Small cell lung Cancer. Mol. Imaging Biol. 25, 228\u2013239. https:\/\/doi.org\/10.1007\/s11307-022-01791-5 (2023).","journal-title":"Mol. Imaging Biol."},{"key":"517_CR21","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/dc.21684","volume":"42","author":"DC Dim","year":"2014","unstructured":"Dim, D. C. et al. The usefulness of S100P, mesothelin, fascin, prostate stem cell antigen, and 14-3-3 Sigma in diagnosing pancreatic adenocarcinoma in cytological specimens obtained by endoscopic ultrasound guided fine-needle aspiration. Diagn. Cytopathol. 42, 193\u2013199. https:\/\/doi.org\/10.1002\/dc.21684 (2014).","journal-title":"Diagn. Cytopathol."},{"key":"517_CR22","doi-asserted-by":"publisher","first-page":"5223","DOI":"10.1002\/cam4.2430","volume":"8","author":"T Li","year":"2019","unstructured":"Li, T. et al. Research progress and design optimization of CAR-T therapy for pancreatic ductal adenocarcinoma. Cancer Med. 8, 5223\u20135231. https:\/\/doi.org\/10.1002\/cam4.2430 (2019).","journal-title":"Cancer Med."},{"key":"517_CR23","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s12885-020-6533-0","volume":"20","author":"PP Almeida","year":"2020","unstructured":"Almeida, P. P., Cardoso, C. P. & de Freitas, L. M. PDAC-ANN: an artificial neural network to predict pancreatic ductal adenocarcinoma based on gene expression. BMC Cancer. 20, 82. https:\/\/doi.org\/10.1186\/s12885-020-6533-0 (2020).","journal-title":"BMC Cancer"},{"key":"517_CR24","doi-asserted-by":"publisher","first-page":"628353","DOI":"10.3389\/fonc.2021.628353","volume":"11","author":"J Gu","year":"2021","unstructured":"Gu, J. et al. TMPRSS4 promotes cell proliferation and inhibits apoptosis in pancreatic ductal adenocarcinoma by activating ERK1\/2 signaling pathway. Front. Oncol. 11, 628353. https:\/\/doi.org\/10.3389\/fonc.2021.628353 (2021).","journal-title":"Front. Oncol."},{"key":"517_CR25","doi-asserted-by":"publisher","unstructured":"Mao, F. et al. High Expression of COL17A1 Predicts Poor Prognosis and Promotes the Tumor Progression via NF-kappaB Pathway in Pancreatic Adenocarcinoma. J Oncol 8868245, (2020). https:\/\/doi.org\/10.1155\/2020\/8868245 (2020).","DOI":"10.1155\/2020\/8868245"},{"key":"517_CR26","doi-asserted-by":"publisher","unstructured":"Long, N. P. et al. An integrative data mining and Omics-Based translational model for the identification and validation of oncogenic biomarkers of pancreatic Cancer. Cancers (Basel). 11 https:\/\/doi.org\/10.3390\/cancers11020155 (2019).","DOI":"10.3390\/cancers11020155"},{"key":"517_CR27","doi-asserted-by":"publisher","first-page":"3530","DOI":"10.1021\/acs.molpharmaceut.1c00947","volume":"19","author":"C Zhao","year":"2022","unstructured":"Zhao, C. et al. Targeting Claudin 18.2 using a highly specific antibody enables Cancer diagnosis and guided surgery. Mol. Pharm. 19, 3530\u20133541. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.1c00947 (2022).","journal-title":"Mol. Pharm."},{"key":"517_CR28","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1002\/ijc.28400","volume":"134","author":"S Woll","year":"2014","unstructured":"Woll, S. et al. Claudin 18.2 is a target for IMAB362 antibody in pancreatic neoplasms. Int. J. Cancer. 134, 731\u2013739. https:\/\/doi.org\/10.1002\/ijc.28400 (2014).","journal-title":"Int. J. Cancer"},{"key":"517_CR29","doi-asserted-by":"publisher","first-page":"155537","DOI":"10.1016\/j.prp.2024.155537","volume":"262","author":"K Maeda","year":"2024","unstructured":"Maeda, K., Uehara, T., Hosoda, W., Kuraishi, Y. & Ota, H. Expression profiles of Cadherin 17 and Claudin 18.2 in comparison with peptide hormonal expression in pancreatic neuroendocrine tumours: implications for targeted immunotherapy. Pathol. Res. Pract. 262, 155537. https:\/\/doi.org\/10.1016\/j.prp.2024.155537 (2024).","journal-title":"Pathol. Res. Pract."},{"key":"517_CR30","doi-asserted-by":"publisher","first-page":"890193","DOI":"10.3389\/fonc.2022.890193","volume":"12","author":"G Chen","year":"2022","unstructured":"Chen, G. et al. AQP5 is a novel prognostic biomarker in pancreatic adenocarcinoma. Front. Oncol. 12, 890193. https:\/\/doi.org\/10.3389\/fonc.2022.890193 (2022).","journal-title":"Front. Oncol."},{"key":"517_CR31","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1002\/jso.24605","volume":"115","author":"I Direito","year":"2017","unstructured":"Direito, I., Paulino, J., Vigia, E., Brito, M. A. & Soveral, G. Differential expression of aquaporin-3 and aquaporin-5 in pancreatic ductal adenocarcinoma. J. Surg. Oncol. 115, 980\u2013996. https:\/\/doi.org\/10.1002\/jso.24605 (2017).","journal-title":"J. Surg. Oncol."},{"key":"517_CR32","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1136\/gut.52.7.1008","volume":"52","author":"B Burghardt","year":"2003","unstructured":"Burghardt, B. et al. Distribution of Aquaporin water channels AQP1 and AQP5 in the ductal system of the human pancreas. Gut 52, 1008\u20131016. https:\/\/doi.org\/10.1136\/gut.52.7.1008 (2003).","journal-title":"Gut"},{"key":"517_CR33","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1007\/s11307-016-0959-4","volume":"18","author":"SW de Geus","year":"2016","unstructured":"de Geus, S. W. et al. Selecting Tumor-Specific molecular targets in pancreatic adenocarcinoma: paving the way for Image-Guided pancreatic surgery. Mol. Imaging Biol. 18, 807\u2013819. https:\/\/doi.org\/10.1007\/s11307-016-0959-4 (2016).","journal-title":"Mol. Imaging Biol."},{"key":"517_CR34","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1158\/1541-7786.MCR-17-0378","volume":"16","author":"MQ Ding","year":"2018","unstructured":"Ding, M. Q., Chen, L., Cooper, G. F., Young, J. D. & Lu, X. Precision oncology beyond targeted therapy: combining omics data with machine learning matches the majority of Cancer cells to effective therapeutics. Mol. Cancer Res. 16, 269\u2013278. https:\/\/doi.org\/10.1158\/1541-7786.MCR-17-0378 (2018).","journal-title":"Mol. Cancer Res."},{"key":"517_CR35","doi-asserted-by":"publisher","first-page":"624","DOI":"10.3389\/fgene.2019.00624","volume":"10","author":"NK Mishra","year":"2019","unstructured":"Mishra, N. K., Southekal, S. & Guda, C. Survival analysis of Multi-Omics data identifies potential prognostic markers of pancreatic ductal adenocarcinoma. Front. Genet. 10, 624. https:\/\/doi.org\/10.3389\/fgene.2019.00624 (2019).","journal-title":"Front. Genet."},{"key":"517_CR36","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1089\/dna.2021.0878","volume":"41","author":"F Jiang","year":"2022","unstructured":"Jiang, F. et al. Integrated analysis of Multi-Omics data to identify prognostic genes for pancreatic Cancer. DNA Cell. Biol. 41, 305\u2013318. https:\/\/doi.org\/10.1089\/dna.2021.0878 (2022).","journal-title":"DNA Cell. Biol."},{"key":"517_CR37","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.bcp.2010.05.018","volume":"80","author":"DL Morse","year":"2010","unstructured":"Morse, D. L. et al. Identification of novel pancreatic adenocarcinoma cell-surface targets by gene expression profiling and tissue microarray. Biochem. Pharmacol. 80, 748\u2013754. https:\/\/doi.org\/10.1016\/j.bcp.2010.05.018 (2010).","journal-title":"Biochem. Pharmacol."},{"key":"517_CR38","doi-asserted-by":"publisher","first-page":"180061","DOI":"10.1038\/sdata.2018.61","volume":"5","author":"Q Wang","year":"2018","unstructured":"Wang, Q. et al. Unifying cancer and normal RNA sequencing data from different sources. Sci. Data. 5, 180061. https:\/\/doi.org\/10.1038\/sdata.2018.61 (2018).","journal-title":"Sci. Data"},{"key":"517_CR39","doi-asserted-by":"publisher","first-page":"115189","DOI":"10.1016\/j.bmc.2019.115189","volume":"28","author":"T Ui","year":"2020","unstructured":"Ui, T. et al. Development and characterization of a (68)Ga-labeled A20FMDV2 peptide probe for the PET imaging of alphavbeta6 integrin-positive pancreatic ductal adenocarcinoma. Bioorg. Med. Chem. 28, 115189. https:\/\/doi.org\/10.1016\/j.bmc.2019.115189 (2020).","journal-title":"Bioorg. Med. Chem."},{"key":"517_CR40","doi-asserted-by":"publisher","first-page":"10467","DOI":"10.1038\/s41598-018-28059-9","volume":"8","author":"J Odenthal","year":"2018","unstructured":"Odenthal, J. et al. Targeting CD44v6 for fluorescence-guided surgery in head and neck squamous cell carcinoma. Sci. Rep. 8, 10467. https:\/\/doi.org\/10.1038\/s41598-018-28059-9 (2018).","journal-title":"Sci. Rep."},{"key":"517_CR41","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.cell.2016.03.014","volume":"165","author":"Y Liu","year":"2016","unstructured":"Liu, Y., Beyer, A. & Aebersold, R. On the dependency of cellular protein levels on mRNA abundance. Cell 165, 535\u2013550. https:\/\/doi.org\/10.1016\/j.cell.2016.03.014 (2016).","journal-title":"Cell"},{"key":"517_CR42","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1038\/s41598-017-01020-y","volume":"7","author":"YI Kim","year":"2017","unstructured":"Kim, Y. I. et al. Simultaneous detection of EGFR and VEGF in colorectal Cancer using Fluorescence-Raman endoscopy. Sci. Rep. 7, 1035. https:\/\/doi.org\/10.1038\/s41598-017-01020-y (2017).","journal-title":"Sci. Rep."},{"key":"517_CR43","doi-asserted-by":"publisher","first-page":"e0121314","DOI":"10.1371\/journal.pone.0121314","volume":"10","author":"D Bausch-Fluck","year":"2015","unstructured":"Bausch-Fluck, D. et al. A mass spectrometric-derived cell surface protein atlas. PLoS One. 10, e0121314. https:\/\/doi.org\/10.1371\/journal.pone.0121314 (2015).","journal-title":"PLoS One"},{"key":"517_CR44","doi-asserted-by":"publisher","first-page":"E10988","DOI":"10.1073\/pnas.1808790115","volume":"115","author":"D Bausch-Fluck","year":"2018","unstructured":"Bausch-Fluck, D. et al. The in Silico human surfaceome. Proc. Natl. Acad. Sci. U S A. 115, E10988\u2013E10997. https:\/\/doi.org\/10.1073\/pnas.1808790115 (2018).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"517_CR45","doi-asserted-by":"publisher","unstructured":"Fonseca, A. L. et al. Bioinformatics analysis of the human surfaceome reveals new targets for a variety of tumor types. Int. J. Genomics. 2016 (8346198). https:\/\/doi.org\/10.1155\/2016\/8346198 (2016).","DOI":"10.1155\/2016\/8346198"},{"key":"517_CR46","doi-asserted-by":"publisher","first-page":"16752","DOI":"10.1073\/pnas.0907939106","volume":"106","author":"JP da Cunha","year":"2009","unstructured":"da Cunha, J. P. et al. Bioinformatics construction of the human cell surfaceome. Proc. Natl. Acad. Sci. U S A. 106, 16752\u201316757. https:\/\/doi.org\/10.1073\/pnas.0907939106 (2009).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"517_CR47","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1038\/s43018-020-00121-4","volume":"1","author":"NG Steele","year":"2020","unstructured":"Steele, N. G. et al. Multimodal mapping of the tumor and peripheral blood immune landscape in human pancreatic Cancer. Nat. Cancer. 1, 1097\u20131112. https:\/\/doi.org\/10.1038\/s43018-020-00121-4 (2020).","journal-title":"Nat. Cancer"},{"key":"517_CR48","doi-asserted-by":"publisher","first-page":"20560","DOI":"10.1038\/s41598-020-76603-3","volume":"10","author":"J Goedhart","year":"2020","unstructured":"Goedhart, J. & Luijsterburg, M. S. VolcaNoseR is a web app for creating, exploring, labeling and sharing volcano plots. Sci. Rep. 10, 20560. https:\/\/doi.org\/10.1038\/s41598-020-76603-3 (2020).","journal-title":"Sci. Rep."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-00517-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-00517-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-00517-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T13:25:01Z","timestamp":1747401901000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-00517-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,16]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["517"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-00517-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,16]]},"assertion":[{"value":"16 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All procedures involving human participants complied with the ethical standards of the institutional and\/or national research committee and followed the principles outlined in the 1964 Helsinki Declaration, including its amendments or equivalent ethical standards. The Ethics Committee of the Leiden University Medical Center reviewed and approved this study (protocol code B20.052, approval date: 17 December 2020). The requirement for informed consent was waived by the Ethics Committee.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"17102"}}